Nexavar is an oral anti-cancer therapy for liver cancer and for the treatment of patients with advanced kidney cancer
As per the deal, Bayer will have the final decision-making authority for global development and commercialization of regorafenib.
Onyx on the other hand will receive a royalty on any future global net sales of regorafenib.
Onyx CEO N Anthony Coles said the new deal would reinforce the collaboration and provide an opportunity to participate in the market potential of regorafenib.